Discover
KYMR
Kymera Therapeutics, Inc.
112.40
2 x 75.27
2 x 133.99
bid
ask
+
3.10
2.84%
2 @ 04:00 PM
112.40 +0.00 (0.00%)
| Ytd | 44.45% | |
| 1y | 97.12% |
107.46
day range
115.81
55.80
52 week range
127.31
| Open | 109.54 | Prev Close | 109.30 | Low | 107.46 | High | 115.81 | Mkt Cap | 9.25B |
| Vol | 1.31M | Avg Vol | 705.63K | EPS | -3.34 | P/E | N/A | Forward P/E | -22.10 |
| Beta | 1.98 | Short Ratio | 16.35 | Inst. Own | 119.36% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-03 | 50-d Avg | 114.50 | 200-d Avg | 93.55 | 1yr Est | 139.32 |
| Income Statement | |||
| Total Revenue | 65.00M | ||
| Revenues (USD) | 65.00M | ||
| Gross Profit | 65.00M | ||
| Operating Expenses | 140.61M | ||
| Research and Development Expense | 119.48M | ||
| Selling, General and Administrative Expense | 21.13M | ||
| Operating Income | -75.61M | ||
| Interest Expense | 81.00K | ||
| Net Income | -61.21M | ||
| Net Income Common Stock | -61.21M | ||
| Net Income Common Stock (USD) | -61.21M | ||
| Consolidated Income | -61.21M | ||
| Earnings per Basic Share | -0.62 | ||
| Earnings per Basic Share (USD) | -0.62 | ||
| Earnings per Diluted Share | -0.62 | ||
| Earning Before Interest & Taxes (EBIT) | -61.13M | ||
| Earning Before Interest & Taxes (USD) | -61.13M | ||
| Weighted Average Shares | 98.18M | ||
| Weighted Average Shares Diluted | 98.18M | ||
| Balance Sheet | |||
| Cash and Equivalents | 130.30M | ||
| Cash and Equivalents (USD) | 130.30M | ||
| Investments | 1.38B | ||
| Investments Current | 566.51M | ||
| Investments Non-Current | 813.90M | ||
| Trade and Non-Trade Receivables | 20.00M | ||
| Current Assets | 737.27M | ||
| Property, Plant & Equipment Net | 81.07M | ||
| Total Assets | 1.65B | ||
| Debt Current | 13.70M | ||
| Total Debt | 78.56M | ||
| Current Liabilities | 71.33M | ||
| Debt Non-Current | 64.86M | ||
| Total Liabilities | 136.19M | ||
| Accumulated Retained Earnings (Deficit) | -1.20B | ||
| Accumulated Other Comprehensive Income | -7.16M | ||
| Shareholders Equity | 1.51B | ||
| Shareholders Equity (USD) | 1.51B | ||
| Assets Non-Current | 908.18M | ||
| Total Debt (USD) | 78.56M | ||
| Liabilities Non-Current | 64.86M | ||
| Trade and Non-Trade Payables | 8.92M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 2.03M | ||
| Net Cash Flow from Financing | 14.42M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -19.60M | ||
| Capital Expenditure | -473.00K | ||
| Issuance (Purchase) of Equity Shares | 14.86M | ||
| Issuance (Repayment) of Debt Securities | -436.00K | ||
| Net Cash Flow from Investing | 20.05M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 20.52M | ||
| Net Cash Flow from Operations | -54.06M | ||
| Share Based Compensation | 18.94M | ||